Vor Biopharma
49 hedge funds and large institutions have $1.31B invested in Vor Biopharma in 2021 Q1 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.14% more ownership
Funds ownership: 0% → 4.14% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$470M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
+$283M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$156M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$48.8M |
| 5 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
+$45.5M |
Top Sellers
VOR Hedge Fund Activity: Q1 2021 in Review
49 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2021, worth a combined $1.31B.
Buyers outnumbered sellers: 49 funds opened new VOR positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $470M.
- 49 institutional investors held Vor Biopharma (VOR) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $1.31B of Vor Biopharma stock for Q1 2021.
- 49 funds opened new Vor Biopharma positions in Q1 2021 and 0 closed out, a net change of +49 holders.
- The largest Vor Biopharma buyer in Q1 2021 was RA Capital Management, an estimated $470M added.
Based on aggregated 13F filings for Q1 2021.